vistusertib: Clinical Trials

20 trials of vistusertib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 terminated, 5 completed, 3 active not recruiting, 2 unknown. 20 Phase 2, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 220Terminated 7, Completed 5, Active not recruiting 3, Unknown 2, Withdrawn 2, Recruiting 1
Phase 15Terminated 2, Unknown 2, Recruiting 1

Follow vistusertib: new trials by email Literature Review of vistusertib trials Research Report on vistusertib

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
Navitoclax, Vistusertib - Metastatic Malignant Solid Neoplasm, Recurrent Lung Small Cell Carcinoma
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)152018-03-202023-10-17
Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy
Vistusertib(AZD2014) - Solid Tumor
Phase 2WithdrawnSamsung Medical Center2018-03-012019-05-20
Phase II Trial of Vistusertib(AZD2014) Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy
Vistusertib(AZD2014) - Solid Tumor
Phase 2WithdrawnSamsung Medical Center2018-03-012019-05-20
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
Durvalumab, Danvatirsen, Ceralasertib - Non-Small Cell Lung Cancer
Phase 2Active not recruitingAstraZeneca5282017-12-182025-10-27
Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
AZD2014 - Meningioma
Phase 2Active not recruitingMassachusetts General Hospital282017-10-172022-10-18
Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification
vistusertib (AZD2014) - Small Cell Lung Cancer
Phase 2TerminatedSamsung Medical Center42017-08-022018-09-20
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
acalabrutinib, vistusertib - DLBCL, Richter Syndrome
Phase 1 / Phase 2TerminatedAcerta Pharma BV252017-06-292021-01-06
Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy
AZD2014 - Stomach Neoplasms
Phase 2TerminatedSamsung Medical Center12017-02-012019-05-20
Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy
AZD2014 - Cancer of Stomach
Phase 2TerminatedSamsung Medical Center12017-02-012019-05-20
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
AZD2014 - Neurofibromatosis 2, Meningioma
Phase 2CompletedMassachusetts General Hospital182016-08-312022-06-13
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Ribociclib, Topotecan, Temozolomide - Pediatric Cancer
Phase 1 / Phase 2RecruitingGustave Roussy, Cancer Campus, Grand Paris4722016-08-032026-07-10
Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)
AZD2014, Anastrozole - Endometrial Carcinoma, Metastatic Carcinoma
Phase 1 / Phase 2UnknownCentre Leon Berard722016-04-012024-02-13
An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma
AZD 2014, Rituximab - Diffuse Large B-Cell Lymphoma
Phase 2CompletedUniversity of Birmingham362015-10-012020-11-05
A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers
AZD2014, AZD6244 - Triple-Negative Breast Cancer, Squamous Cell Lung Cancer
Phase 1 / Phase 2UnknownQueen Mary University of London1182015-06-012020-02-25
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
AZD4547, Vistusertib, Palbociclib - Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell
Phase 2CompletedUniversity of Birmingham4232015-05-132026-04-28
Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy
AZD5363, paclitaxel, AZD2014 - Advanced Gastric Adenocarcinoma
Phase 2TerminatedSamsung Medical Center272015-02-122019-05-20
SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients
AZD2014, AZD4547, AZD5363 - Non-small Cell Lung Cancer Metastatic
Phase 2CompletedUNICANCER9992014-04-232024-01-10
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
AZD2014, AZD4547, AZD5363 - Metastatic Breast Cancer
Phase 2Active not recruitingUNICANCER14602014-04-072025-01-15
A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer
AZD2014, Everolimus, Fulvestrant - Estrogen Receptor Positive Breast Cancer
Phase 2CompletedQueen Mary University of London3332014-01-162024-12-02
A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer
AZD2014, Everolimus - Metastatic Clear Cell Renal Carcinoma
Phase 2TerminatedQueen Mary University of London492013-02-012014-06-24

Conditions studied

Carcinoma, Non-Small-Cell Lung (2)  ·  Meningioma (2)  ·  Small Cell Lung Carcinoma (2)  ·  Stomach Neoplasms (2)  ·  Adenocarcinoma (1)  ·  Breast Neoplasms (1)  ·  Carcinoma (1)  ·  Carcinoma, Renal Cell (1)  ·  Carcinoma, Squamous Cell (1)  ·  Endometrial Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Lymphoma (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasms (1)

Sponsors

Samsung Medical Center (6)  ·  Queen Mary University of London (3)  ·  Massachusetts General Hospital (2)  ·  UNICANCER (2)  ·  University of Birmingham (2)  ·  Acerta Pharma BV (1)  ·  AstraZeneca (1)  ·  Centre Leon Berard (1)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)  ·  National Cancer Institute (NCI) (1)

Countries

South Korea (8)  ·  United Kingdom (7)  ·  France (6)  ·  United States (5)  ·  Spain (3)  ·  Germany (2)  ·  Austria (1)  ·  Canada (1)  ·  Denmark (1)  ·  Georgia (1)  ·  Hungary (1)  ·  Israel (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Portugal (1)

Top investigators

Birgit Geoerger, MD (1)  ·  Christine L Hann (1)  ·  Gary W Middleton (1)  ·  Graham Collins, MBBS DPhil (1)  ·  Jeeyun Lee, Md,PhD (1)  ·  John Heymach, M.D, Ph.D (1)  ·  Peter Schmid, Prof (1)  ·  Peter Schmid, Professor (1)  ·  Scott Plotkin, MD, PhD (1)  ·  Scott R. Plotkin, MD, PhD (1)

Results publications

PMID 26410619, PMID 31465093, PMID 31538815, PMID 32067679, PMID 32669708, PMID 33892407, PMID 34269152, PMID 34347542, PMID 34543871, PMID 35292802, PMID 35551299, PMID 38351187, PMID 39998620, PMID 40069402, PMID 41838385, PMID 42686334

NIH funding

2014 (2), 2016 (1), 2017 (1), 2023 (1), R01CA201130 (1), UM1CA186691 (1)